Optimizing the risk threshold of lymph node involvement for performing extended pelvic lymph node dissection in prostate cancer patients: a cost-effectiveness analysis

被引:2
作者
Hueting, Tom [1 ]
Cornel, Erik [2 ]
Korthorst, Ruben [3 ]
Pleijhuis, Rick [4 ]
Somford, Diederik [5 ]
van Basten, Jean-Paul [5 ]
van der Palen, Job [6 ]
Koffijberg, Hendrik H. [1 ]
机构
[1] Univ Twente, Tech Med Ctr, Dept Hlth Technol & Serv Res, Enschede, Netherlands
[2] Ziekenhuisgrp Twente, Dept Urol, Hengelo, Netherlands
[3] Med Spectrum Twente, Dept Urol, Enschede, Netherlands
[4] Univ Med Ctr Groningen, Dept Internal Med, Groningen, Netherlands
[5] Canisius Wilhelmina Ziekenhuis, Dept Urol, Nijmegen, Netherlands
[6] Univ Twente, Fac Behav Management & Social Sci Res Methodol Me, Med Spectrum Twente, Enschede, Netherlands
关键词
RADICAL PROSTATECTOMY; MEN; LYMPHADENECTOMY; VALIDATION; IMMEDIATE; OUTCOMES; ANTIGEN; IMPACT;
D O I
10.1016/j.urolonc.2020.09.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Extended pelvic lymph node dissection (ePLND) may be omitted in prostate cancer (CaP) patients with a low predicted risk of lymph node involvement (LNI). The aim of the current study was to quantify the cost-effectiveness of using different risk thresholds for predicted LNI in CaP patients to inform decision making on omitting ePLND. Methods: Five different thresholds (2%, 5%, 10%, 20%, and 100%) used in practice for performing ePLND were compared using a decision analytic cohort model with the 100% threshold (i.e., no ePLND) as reference. Compared outcomes consisted of quality-adjusted life years (QALYs) and costs. Baseline characteristics for the hypothetical cohort were based on an actual Dutch patient cohort containing 925 patients who underwent ePLND with risks of LNI predicted by the Memorial Sloan Kettering Cancer Center web-calculator. The best strategy was selected based on the incremental cost effectiveness ratio when applying a willingness to pay (WTP) threshold of (sic)20,000 per QALY gained. Probabilistic sensitivity analysis was performed with Monte Carlo simulation to assess the robustness of the results. Results: Costs and health outcomes were lowest ((sic)4,858 and 6.04 QALYs) for the 100% threshold, and highest ((sic)10,939 and 6.21 QALYs) for the 2% threshold, respectively. The incremental cost effectiveness ratio for the 2%, 5%, 10%, and 20% threshold compared with the first threshold above (i.e., 5%, 10%, 20%, and 100%) were (sic)189,222/QALY, (sic)130,689/QALY, (sic)51,920/QALY, and (sic)23,187/QALY respectively. Applying a WTP threshold of (sic)20.000 the probabilities for the 2%, 5%, 10%, 20%, and 100% threshold strategies being cost-effective were 0.0%, 0.3%, 4.9%, 30.3%, and 64.5% respectively. Conclusion: Applying a WTP threshold of (sic)20.000, completely omitting ePLND in CaP patients is cost-effective compared to other risk-based strategies. However, applying a 20% threshold for probable LNI to the Briganti 2012 nomogram or the Memorial Sloan Kettering Cancer Center web-calculator, may be a feasible alternative, in particular when higher WTP values are considered. (C) 2020 The Authors. Published by Elsevier Inc.
引用
收藏
页码:72.e7 / 72.e14
页数:8
相关论文
共 31 条
  • [1] Allaf Mohamad E, 2006, Rev Urol, V8, P112
  • [2] [Anonymous], 2019, PRIC
  • [3] Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist
    Bamber L.
    Muston D.
    McLeod E.
    Guillermin A.
    Lowin J.
    Patel R.
    [J]. Thrombosis Journal, 13 (1)
  • [4] No impact of blood transfusion on oncological outcome after radical prostatectomy in patients with prostate cancer
    Boehm, K.
    Beyer, B.
    Tennstedt, P.
    Schiffmann, J.
    Budaeus, L.
    Haese, A.
    Graefen, M.
    Schlomm, T.
    Heinzer, H.
    Salomon, G.
    [J]. WORLD JOURNAL OF UROLOGY, 2015, 33 (06) : 801 - 806
  • [5] Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era
    Boorjian, Stephen A.
    Thompson, R. Houston
    Siddiqui, Sameer
    Bagniewski, Stephanie
    Bergstralh, Erik J.
    Karnes, R. Jeffrey
    Frank, Igor
    Blute, Michael L.
    [J]. JOURNAL OF UROLOGY, 2007, 178 (03) : 864 - 870
  • [6] Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores
    Briganti, Alberto
    Larcher, Alessandro
    Abdollah, Firas
    Capitanio, Umberto
    Gallina, Andrea
    Suardi, Nazareno
    Bianchi, Marco
    Sun, Maxine
    Freschi, Massimo
    Salonia, Andrea
    Karakiewicz, Pierre I.
    Rigatti, Patrizio
    Montorsi, Francesco
    [J]. EUROPEAN UROLOGY, 2012, 61 (03) : 480 - 487
  • [7] Pelvic Lymph Node Dissection in Prostate Cancer
    Briganti, Alberto
    Blute, Michael L.
    Eastham, James H.
    Graefen, Markus
    Heidenreich, Axel
    Karnes, Jeffrey R.
    Montorsi, Francesco
    Studer, Urs E.
    [J]. EUROPEAN UROLOGY, 2009, 55 (06) : 1251 - 1265
  • [8] Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis
    Cooperberg, Matthew R.
    Ramakrishna, Naren R.
    Duff, Steven B.
    Hughes, Kathleen E.
    Sadownik, Sara
    Smith, Joseph A.
    Tewari, Ashutosh K.
    [J]. BJU INTERNATIONAL, 2013, 111 (03) : 437 - 450
  • [9] Long-Term Follow-up of Patients with Prostate Cancer and Nodal Metastases Treated by Pelvic Lymphadenectomy and Radical Prostatectomy: The Positive Impact of Adjuvant Radiotherapy
    Da Pozzo, Luigi F.
    Cozzarini, Cesare
    Briganti, Alberto
    Suardi, Nazareno
    Salonia, Andrea
    Bertini, Roberto
    Gallina, Andrea
    Bianchi, Marco
    Fantini, Gemma V.
    Bolognesi, Angelo
    Fazio, Ferruccio
    Montorsi, Francesco
    Rigatti, Patrizio
    [J]. EUROPEAN UROLOGY, 2009, 55 (05) : 1003 - 1011
  • [10] Long-Term Survival in a Large Cohort of Patients with Venous Thrombosis: Incidence and Predictors
    Flinterman, Linda E.
    Vlieg, Astrid van Hylckama
    Cannegieter, Suzanne C.
    Rosendaal, Frits R.
    [J]. PLOS MEDICINE, 2012, 9 (01)